These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 34647511)

  • 1. Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19.
    Zarei M; Sahebi Vaighan N; Ziai SA
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):633-643. PubMed ID: 34647511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
    Shawki MA; Elsayed NS; Mantawy EM; Said RS
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.
    Hasan D; Shono A; van Kalken CK; van der Spek PJ; Krenning EP; Kotani T
    Purinergic Signal; 2022 Mar; 18(1):13-59. PubMed ID: 34757513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phytotherapy for treatment of cytokine storm in COVID-19.
    Sapra L; Bhardwaj A; Azam Z; Madhry D; Verma B; Rathore S; Srivastava RK
    Front Biosci (Landmark Ed); 2021 Apr; 26(5):51-75. PubMed ID: 34027650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
    Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
    Azar MM; Shin JJ; Kang I; Landry M
    Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
    Mohanty RR; Padhy BM; Das S; Meher BR
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2802-2807. PubMed ID: 33829465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
    Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
    England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
    Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.
    Leão Batista Simões J; Fornari Basso H; Cristine Kosvoski G; Gavioli J; Marafon F; Elias Assmann C; Barbosa Carvalho F; Dulce Bagatini M
    Int Immunopharmacol; 2021 Nov; 100():108150. PubMed ID: 34537482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine storm syndrome in coronavirus disease 2019: A narrative review.
    Gao YM; Xu G; Wang B; Liu BC
    J Intern Med; 2021 Feb; 289(2):147-161. PubMed ID: 32696489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cytokine Circus with a Viral Ringleader: SARS-CoV-2-Associated Cytokine Storm Syndromes.
    Cabler SS; French AR; Orvedahl A
    Trends Mol Med; 2020 Dec; 26(12):1078-1085. PubMed ID: 33051104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
    Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
    Front Immunol; 2021; 12():749291. PubMed ID: 34867978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
    Taghiloo S; Soltanshahi M; Aliyali M; Abedi S; Mehravaran H; Ajami A; Asgarian-Omran H
    Iran J Immunol; 2021 Mar; 18(1):54-64. PubMed ID: 33787514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
    Gangemi S; Tonacci A
    Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
    Ahmed F
    Front Immunol; 2020; 11():590459. PubMed ID: 33362771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
    Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
    Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.